针对B族链球菌的孕产妇免疫接种:全球健康影响与成本效果分析
BACKGROUND: Group B Streptococcus (GBS) can cause invasive disease (iGBS) in young infants, typically presenting as sepsis or meningitis, and is also associated with stillbirth and preterm birth.…
要点
- 孕产妇GBS疫苗接种可大幅减少婴儿iGBS发病和死亡。
- 疫苗价格合理时,全球范围内可能具有成本效果。
核心结论
- 孕产妇GBS疫苗接种对婴儿发病和死亡可能有很大影响,价格合理时可能具有成本效果。
研究设计与样本
- 假设疫苗对iGBS和死胎效力为80%,覆盖基于至少4次产前检查的孕妇比例。
- 一剂疫苗价格假设为高收入国家50美元、中高收入国家15美元、中低收入/低收入国家3.50美元。
主要发现
- 接种可避免127,000(95%不确定性范围63,300至248,000)例早发型和87,300(38,100至209,000)例晚发型婴儿iGBS病例。
- 接种可避免31,100例死亡(14,400至66,400)、17,900例(6,380至49,900)中重度神经发育障碍和23,000例(10,000至56,400)死胎。
- 针对GBS相关早产的疫苗可能避免185,000例(13,500至407,000)早产。
局限性
- 主要局限性是缺乏数据来指导某些模型参数,如健康相关生活质量和残疾长期成本,以及这些参数在不同国家背景下的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Group B Streptococcus (GBS) can cause invasive disease (iGBS) in young infants, typically presenting as sepsis or meningitis, and is also associated with stillbirth and preterm birth. GBS vaccines are under development, but their potential health impact and cost-effectiveness have not been assessed globally. METHODS AND FINDINGS: We assessed the health impact and value (using net monetary benefit (NMB), which measures both health and economic effects of vaccination into monetary units) of GBS maternal vaccination in an annual cohort of 140 million pregnant women across 183 countries in 2020. Our analysis uses a decision tree model, incorporating risks of GBS-related health outcomes from an existing Bayesian disease burden model. We extrapolated country-specific GBS-related healthcare costs using data from a previous systematic review and calculated quality-adjusted life years (QALYs) lost due to infant mortality and long-term disability. We assumed 80% vaccine efficacy against iGBS and stillbirth, following the WHO Preferred Product Characteristics, and coverage based on the proportion of pregnant women receiving at least 4 antenatal visits. One dose was assumed to cost $50 in high-income countries, $15 in upper-middle income countries, and $3.50 in low-/lower-middle-income countries. We estimated NMB using alternative normative assumptions that may be adopted by policymakers. Vaccinating pregnant women could avert 127,000 (95% uncertainty range 63,300 to 248,000) early-onset and 87,300 (38,100 to 209,000) late-onset infant iGBS cases, 31,100 deaths (14,400 to 66,400), 17,900 (6,380 to 49,900) cases of moderate and severe neurodevelopmental impairment, and 23,000 (10,000 to 56,400) stillbirths. A vaccine effective against GBS-associated prematurity might also avert 185,000 (13,500 to 407,000) preterm births. Globally, a 1-dose vaccine programme could cost $1.7 billion but save $385 million in healthcare costs. Estimated global NMB ranged from $1.1 billion ($-0.2 to 3.8 billion) under the least favourable normative assumptions to $17 billion ($9.1 to 31 billion) under the most favourable normative assumptions. The main limitation of our analysis was the scarcity of data to inform some of the model parameters such as those governing health-related quality of life and long-term costs from disability, and how these parameters may vary across country contexts. CONCLUSIONS: In this study, we found that maternal GBS vaccination could have a large impact on infant morbidity and mortality. Globally, a GBS maternal vaccine at reasonable prices is likely to be a cost-effective intervention.
引用
- Procter SR, Gonçalves BP, Paul P, et al. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness. PLoS Med. 2023. PMID: 36917564. doi:10.1371/journal.pmed.1004068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。